PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

CannaLean Develops New Cannabidiol & Chitosan Formulation to Safely Lower Cholesterol and Triglyceride Levels; A Stain Alternative with Fewer Risks

Tel Aviv, Israel, November 26, 2018…CannaLean, an Israeli company committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from dyslipidemia, has completed in vivo studies showing a significant decrease in cholesterol/triglyceride, demonstrating the potential clinical effect of the novel patent-protected formulation.

There is currently a clinical unmet need to develop a new and safe solution for treating dyslipidemia–reducing the LDL cholesterol and triglyceride levels– without the side effects of currently available therapies.  Its prevalence is very common and as much as 50% of the adult population worldwide suffer from some kind of dyslipidemia.

When lifestyle changes are insufficient to reduce lipid levels (including cholesterol and triglycerides), statins are the most common treatment. While statins are highly effective, they often cause side effects, such as memory loss, muscle pain, digestive problems, and, in the worst cases, liver damage and death. CannaLean is developing an alternative to statins for the reduction of lipids using CBD as the active ingredient.

CannaLean has developed a novel formulation of Cannabidiol (CBD), with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to significantly reduce cholesterol and triglycerides.

Our preliminary in vivo results in animals models show the effect of the novel formulation on cholesterol and triglycerides reduction, as compared to controls and each compound alone.

CannaLean’s Medical Director, Dr. Dror Robinson noted: “High Cholesterol and Triglycerides levels are a serious health problem in our community and being able to effectively lower cholesterol and triglycerides without the use of current drugs solutions such as Statins will be a major breakthrough in lowering the risk of heart attack and stroke. Our unique formulation of cannabidiol and chitosan has shown positive results in in-vivo studies and we look forward to upcoming clinical trials that will provide further evidence for this promising new therapy.”

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40